RecruitingNCT05681975

Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Food-specific Immunoglobulin G4 and Immunoglobulin E Antibody Reactions in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Sponsor

Universidad Politecnica de Madrid

Enrollment

200 participants

Start Date

Oct 1, 2017

Study Type

OBSERVATIONAL

Conditions

Immunoglobulin G4-Related Disease Symptoms and Signs Immunoglobulin E-Mediated Food Allergy Adverse Reaction to Food

Summary

The aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody reactions (AbR).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions for people with adverse reaction to food, immunoglobulin e-mediated food allergy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFood-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions

Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.

Locations(1)

Universidad Politécnica de Madrid

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05681975

Related Trials

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT0719019679 locations

Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers

NCT074155641 location

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

NCT059583165 locations

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

NCT061362212 locations

Integrative Oncology for Patient Symptoms

NCT049407801 location